Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

NCT00272181 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Slow accrual in North America

Conditions

Squamous Cell Carcinoma of the Head and Neck
Carcinoma, Squamous Cell
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Mouth Neoplasms
Head and Neck Cancer

Interventions

DRUG: Proxinium

Sponsor

Sesen Bio, Inc.